share_log

三葉草生物-B：根據許可協議授予延長豁免嚴格遵守上市規則第14A.53條

CLOVER BIO-B: GRANT OF EXTENSION OF WAIVER FROM STRICT COMPLIANCE WITH RULE 14A.53 OF THE LISTING RULES UNDER THE LICENSE AGREEMENT

香港交易所 ·  Dec 27, 2023 17:05
Summary by Moomoo AI
三葉草生物製藥有限公司（「三葉草生物-B」）宣布，根據與GenHunter Corporation（「GenHunter」）的許可協議，公司全資附屬四川三葉草獲得延長豁免嚴格遵守上市規則第14A.53條至2026年12月31日。該許可協議允許四川三葉草在全球範圍內使用GenHunter的Trimer-Tag™技術平台進行藥物開發、生產及商業化，並向GenHunter支付銷售淨額2%的版稅及分許可收入20%的版稅。由於公司執行董事梁博士全資擁有GenHunter，GenHunter被視為關連人士，因此許可協議屬於持續關連交易。公司申請豁免的理由包括商業上不可行、符合公司及股東整體利益、市場敏感性及重新遵守上市規則。聯交所已於2023年11月28日批准豁免申請，並設定相關條件。三葉草生物-B將於2023年12月31日後60日內遞交版稅報告給GenHunter，並於下一份年報中披露。
三葉草生物製藥有限公司（「三葉草生物-B」）宣布，根據與GenHunter Corporation（「GenHunter」）的許可協議，公司全資附屬四川三葉草獲得延長豁免嚴格遵守上市規則第14A.53條至2026年12月31日。該許可協議允許四川三葉草在全球範圍內使用GenHunter的Trimer-Tag™技術平台進行藥物開發、生產及商業化，並向GenHunter支付銷售淨額2%的版稅及分許可收入20%的版稅。由於公司執行董事梁博士全資擁有GenHunter，GenHunter被視為關連人士，因此許可協議屬於持續關連交易。公司申請豁免的理由包括商業上不可行、符合公司及股東整體利益、市場敏感性及重新遵守上市規則。聯交所已於2023年11月28日批准豁免申請，並設定相關條件。三葉草生物-B將於2023年12月31日後60日內遞交版稅報告給GenHunter，並於下一份年報中披露。
Clover Biopharmaceuticals Limited (“Clover Bio-B”) announces that under a licensing agreement with GenHunter Corporation (“GenHunter”), the Company's wholly-owned subsidiary Sichuan Clover has been granted an extended exemption in strict compliance with Listing Rules Section 14A.53 through December 31, 2026. The license agreement allows Sichuan Clover to use GenHunter's Trimer-Tag™ technology platform globally for drug development, production and commercialization, and to pay GenHunter a royalty of 2% of net sales and a royalty of 20% on licensed revenue. Since the Company's Executive Director, Dr. Leung is wholly owned by GenHunter, GenHunter is considered to be a connected person, so the license agreement is a continuing connected transaction. The Company's reasons for applying for exemption include commercial impracticability, compliance with...Show More
Clover Biopharmaceuticals Limited (“Clover Bio-B”) announces that under a licensing agreement with GenHunter Corporation (“GenHunter”), the Company's wholly-owned subsidiary Sichuan Clover has been granted an extended exemption in strict compliance with Listing Rules Section 14A.53 through December 31, 2026. The license agreement allows Sichuan Clover to use GenHunter's Trimer-Tag™ technology platform globally for drug development, production and commercialization, and to pay GenHunter a royalty of 2% of net sales and a royalty of 20% on licensed revenue. Since the Company's Executive Director, Dr. Leung is wholly owned by GenHunter, GenHunter is considered to be a connected person, so the license agreement is a continuing connected transaction. The Company's reasons for applying for exemption include commercial impracticability, compliance with the overall interests of the company and shareholders, market sensitivity and re-compliance with listing rules. The exchange approved the exemption application on 28 November 2023 and set the relevant conditions. Clover Bio-B will file a royalty report with GenHunter within 60 days of December 31, 2023 and will be disclosed in the next annual report.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more